The contents of this website are intended for US healthcare professionals only.

Indication

RYSTIGGO (rozanolixizumab-noli) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

For US Healthcare Professionals Only Full Prescribing Information | Important Safety Information

Create a New Account

Account Information

Please complete the information below to create an account. If you already have an account and would like to log in, click here.
* Indicates a required field.

*First Name

*Last Name

*NPI

*Email

*Phone Number

*Address 1

Address 2

Address 3

*City

*State

*ZIP

Create Login

*Username

*Password

*Confirm Password